NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Dividends
Nurix Therapeutics has not reported a dividend
No dividend per share appears in Nurix Therapeutics's annual filings since fiscal 2018.